advagraf capsules prolonged-release
astellas ireland co. ltd. - tacrolimus - capsules prolonged-release - 3mg
cartia
padagis israel agencies ltd, israel - acetylsalicylic acid - tablets enteric coated - acetylsalicylic acid 100 mg - acetylsalicylic acid - acetylsalicylic acid - the primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.
amoxil tablets
kievmedpreparat pjsc - amoxicillin (amoxicillin trihydrate) - tablets - 500mg
amoxil tablets
kievmedpreparat pjsc - amoxicillin (amoxicillin trihydrate) - tablets - 250mg
stay safe balance 1.5% glucose 1.75mmoll calcium peritoneal dialysis solution bag
fresenius medical care malaysia sdn bhd - calcium chloride dihydrate ph. eur.; magnesium chloride hexahydrate pheur; glucose monohydrate, ph eur; sodium chloride (nacl); sodium lactate solution (50%) -
stay safe balance 2.3% glucose 1.75 mmoll calcium peritoneal dialysis solution bag
fresenius medical care malaysia sdn bhd - sodium chloride (nacl); calcium chloride dihydrate ph. eur.; magnesium chloride hexahydrate pheur; glucose monohydrate, ph eur; sodium lactate solution (50%) -
stay safe balance 4.25% glucose 1.75 mmoll calcium peritoneal dialysis solution bag
fresenius medical care malaysia sdn bhd - sodium chloride (nacl); calcium chloride dihydrate ph. eur.; magnesium chloride hexahydrate pheur; glucose monohydrate, ph eur; sodium lactate solution (50%) -
dermostamin gel
trima israel pharmaceutical products maabarot ltd - dimetindene maleate - gel - dimetindene maleate 0.1 %w/w - dimetindene - urticaria, pruritis, dermatoses, burns, insect bites, allergic dermatitis and eczema.
betasalic ointment
kievmedpreparat pjsc - betamethasone (betamethasone dipropionate), salicylic acid - ointment - 0,64mg/g+ 30mg/g
vyvanse 50 mg
medison pharma ltd - lisdexamfetamine dimesylate - capsules - lisdexamfetamine dimesylate 50 mg - lisdexamfetamine - vyvanse is a central nervous system (cns) stimulant indicated for the treatment of attention deficit hyperactivity disorder (adhd) in patients ages 6 years and above.vyvanse is indicated for the treatment of moderate to severe binge eating disorder (bed) for patient over 18 years.limitation of use:vyvanse is not indicated or recommended for weight loss. use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. the safety and effectiveness of vyvanse for the treatment of obesity have not been established